Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Wunder

Vascular & Interventional Radiology Goodlettsville, TN Medical Doctor

NPI 1457306565 CMS profile 65237

3024 Business Park Cir, Goodlettsville, TN 37072

Open in the dashboard

General payments

$1,924

80 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Wunder of Goodlettsville, TN is reported in the CMS Open Payments database as having received $1,924 across 80 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 43rd percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $562 19
2024 General $234 9
2023 General $313 17
2022 General $109 6
2021 General $140 7
2020 General $146 8
2019 General $421 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Wunder
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Daniel Wunder were reported at $562. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Daniel Wunder Vascular & Interventional Radiology median Middle half National median
2019 $421 $422 $125–$1,555 $163
2020 $146 $200 $68–$652 $114
2021 $140 $280 $99–$866 $132
2022 $109 $433 $137–$1,497 $149
2023 $313 $506 $152–$2,019 $160
2024 $234 $556 $175–$1,930 $164
2025 $562 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $795 32 payments
  2. Radius Health, Inc. $351 20 payments
  3. Medtronic Vascular, Inc. $197 4 payments
  4. Cook Medical LLC $157 10 payments
  5. Teleflex LLC $112 4 payments
  6. Boston Scientific Corporation $74 1 payment
  7. Bard Peripheral Vascular, Inc. $59 2 payments
  8. Globus Medical, Inc. $36 1 payment
  9. Abbott Laboratories $31 1 payment
  10. Terumo Medical Corporation $30 1 payment
  11. Other $83 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,924 80 payments
Products named General payments · program years 2019–2025
  1. EVENITY $795 32 payments
  2. Prolia $313 19 payments
  3. Tymlos Endocrinology $213 13 payments
  4. IN.PACT Admiral $180 3 payments
  5. Tymlos Endocrinology $137 7 payments
  6. ARROW $95 3 payments
  7. DIREXION $74 1 payment
  8. Cook Medical Angioplasty $50 3 payments
  9. Senza $36 1 payment
  10. Proclaim IPG $31 1 payment
  11. Other $275 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

218

Median for Interventional Radiology: 38

Drug cost

$28,005

Median for Interventional Radiology: $333

Branded share of claims

56.9%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 20 $16,140
Eliquis Apixaban Brand 13 $9,820
Cilostazol Generic 64 $1,012
Clopidogrel Clopidogrel Bisulfate Brand 91 $918
Tizanidine Hcl Generic 30 $115

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 240 billing codes

Paid by Medicare

$609,084

Of which drugs: $7,741

Medicare patients

2,648

Average age 74

Services billed

50,170

1,429 women, 1,219 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 36%
Diabetes 31%
Chronic kidney disease 29%
COPD 22%
Cancer 22%
Depression 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 108 8,648 $2,509
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 177 17,999 $1,865
Injection, methylprednisolone acetate, 1 mg J1010 Office 105 11,361 $1,147
Injection, gadobutrol, 0.1 ml A9585 Office 40 3,572 $872
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 18 75 $417
Injection, gadoterate meglumine, 0.1 ml A9575 Office 20 3,301 $311
Injection, methylprednisolone acetate, 80 mg J1040 Office 23 23 $161
Injection, methylprednisolone acetate, 40 mg J1030 Office 26 29 $141
Injection, fentanyl citrate, 0.1 mg J3010 Office 68 154 $113
Injection, ketorolac tromethamine, per 15 mg J1885 Office 33 126 $71

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $176
$176 — —
Prolia
  • Amgen Inc. $43
$43 — —
Tymlos
  • Radius Health, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

80 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record